Sign inJoin waitlistJoin the waitlist

Brenda Sandmaier

Professor and Deputy Director, Translational Science and Therapeutics Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

University of Washington School of Medicine
1986–1988
Kaiser Permanente Medical Center
1983–1986
Genetics, University of Alberta
UNIV OF ALBERTA, EDMONTON
1979–1983

Research

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Blood · 2005 · 2,577 citations
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Biology of Blood and Marrow Transplantation · 2008 · 1,627 citations
Defining the intensity of conditioning regimens: working definitions
Biology of Blood and Marrow Transplantation · 2009 · 1,558 citations

Rainer Storb
218 papers
David Maloney
111 papers
Frederick Appelbaum
79 papers
MM
Michael Maris
67 papers · 3 as a fellow
Mohamed Sorror
66 papers
TC
Thomas Chauncey
64 papers
Joachim Deeg
56 papers
Mary Flowers
54 papers
Paul Martin
44 papers
PM
Peter Mcsweeney
43 papers
Marco Mielcarek
39 papers
Michael Pulsipher
37 papers

Grants

Preventing Relapse After Non-Myeloablative Stem Cell Transplantation: The Final Challenge
National Cancer Institute · P01
Contact PI · $21.8M · Fred Hutchinson Cancer Center
1999–2027
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
National Institute of Allergy and Infectious Diseases · R33
Contact PI · $1.6M · Fred Hutchinson Cancer Center
2016–2023
Alpha Radioimmunotherapy for Lymphoma Treatment
National Cancer Institute · R01
Contact PI · $3.2M · Fred Hutchinson Cancer Center
2013–2022
Cell and Gene Therapy for Nonmalignant Blood Disorders
National Heart, Lung, and Blood Institute · P01
Project lead · $2.5M · Fred Hutchinson Cancer Center
2022

Clinical trials

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Principal investigator · Recruiting · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2017–2029
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
Principal investigator · Completed · Phase 1
Fred Hutchinson Cancer Center
2012–2019
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2011–2019
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2010–2019